With combination treatments of carboplatin following anti-CLPTM1L treatment, tumor load was decreased (0.23-fold) over 35 days compared to mice treated with carboplatin alone, in which tumor load increased slightly by an average of 1.23-fold (T-test p < 0.05) (Fig. 5d). Here, CLPTM1L is linked to neoplasm.